A combination of docetaxel and a low dose of AGN205728 (10−7 M) showed a substantial reduction in prostate cancer cell viability, revealing that RARγ antagonists combined with chemotherapy may be effective in treating prostate cancer. This evidence concerns the gene RARG and prostate carcinoma.